GSK: Flat Base detected on 13 Nov 2026

All prices, scores, and news on this page reflect data available before market open on .

Free example: 1 of 44 setups from the 13 Nov 2026 scan. Subscribers get the full list every trading day by 6 AM ET.

On 13 Nov 2026, our scan flagged GSK as a flat base setup scoring 75 out of 98 (Good tier), with a 60% win probability based on our historical pattern database and a 0.87 to 1 risk to reward profile from the published levels. This is a swing trade setup: win probability reflects a multi-day swing hold, not an intraday move. At $50.64, the conservative target is $53.09 with a stop at $47.81.

75 of 98
Good
60%
Low
0.87 : 1
$2.45 to target $2.83 to stop
Swing Trading Plan
Entry
$50.64
$53.09
$47.81
3-8 trading days
Exp. Reward
+$1.16
Exp. Risk
-$0.61

Expected figures are probability-weighted from our historical pattern database; Trade R:R is measured from the entry, target and stop levels.

Current Setup
GSK is forming a flat base pattern with overall score of 75.0, combining structure (15.0), volume (12.0), and breakout (13.0) metrics. The stock trades at $50.64 with key support at $45.82 and resistance at $51.89. Pattern quality is solid—not exceptional but above average—with preceding patterns (ascending triangle, bullish pennant) suggesting consolidation after recent moves. Volume is at 2.55M shares, 60% of the 20-day average, which is lighter than ideal but typical during tight consolidation. RSI sits neutral at 54.37, MACD histogram positive at 0.0973, and Bollinger Band position at 0.615 indicates room to run. The setup suggests containment before a potential breakout.
Stock Context
GSK reported Q3 2026 earnings beating EPS estimates, with specialty medicines rising 15% at constant currency to £3.9B driven by strong growth in oncology, HIV, and respiratory drugs. However, vaccine sales fell 2%, underperforming estimates with weak Shingrix and Arexvy sales. The company reaffirmed 2026 guidance for 3-5% turnover growth, 7-9% core operating profit growth, and 7-9% core EPS growth. On November 12, GSK reached a $2.2 billion settlement resolving 93% of outstanding Zantac cancer lawsuits, removing a major litigation overhang. Recent pipeline catalysts include positive Mo-Rez data in platinum-resistant ovarian cancer and Jemperli dostarlimab approval showing 76% complete response rates in locally advanced rectal cancer. The combination of litigation resolution, solid EPS beat, and positive pipeline momentum provides technical foundation for the current consolidation.
What to Expect
A successful breakout above $51.89 resistance would target $53.09 conservatively, representing a 2.9% gain from current levels—modest but meaningful in healthcare pharma. Volume confirmation will be critical; the pattern needs volume expansion above the 20-day average of 4.23M shares at breakout. Invalidation occurs below support at $45.82; a breakdown below this level would negate the constructive setup. The 59.84% win probability indicates better-than-coin-flip odds, though not dominant. Pattern suggests a 3-4 week timeframe for resolution.
Risk Factors
Vaccine segment weakness—Shingrix and Arexvy underperformance—signals demand softness that persists despite specialty medicine strength. While the Zantac settlement provides clarity, GSK must balance legal payments and restructuring costs with R&D investment in oncology, respiratory, HIV, and liver disease. Volume is concerning at 60% of average; low participation limits conviction in the breakout. Beta of 0.67 and 20-day volatility of 0.31% reflect defensive characteristics, limiting explosive upside. Stock sits 15.73% below 52-week highs, suggesting room to run downside if fundamentals disappoint. Monitor Q4 vaccine trends and next earnings guidance closely; any revenue miss could invalidate the consolidation pattern. Analyst mix (Goldman Sachs Neutral, Deutsche Bank Neutral balanced against Bernstein Buy) shows mixed conviction.
How We Find and Score This Setup
We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading. What the terms mean →
Frequently Asked Questions
Is GSK a good swing trade?
GSK scored 75 out of 98 on our flat base scan, with a 60% historical win probability over a 3-8 trading days hold. Good setup based on our systematic scoring.
What is the entry, target, and stop loss for this setup?
The setup's reference price is $50.64, with a conservative target of $53.09 and a stop loss at $47.81.
What would invalidate this flat base setup?
A close below the stop loss at $47.81 would invalidate the setup and suggest the pattern has failed.
How is the win probability calculated?
Win probability is a calibrated estimate of how similar historical flat base setups performed over the following 10 trading days, drawn from a database of 370,000+ historical pattern detections across 6,000+ NYSE and NASDAQ stocks.
Market & Sector Regime
Market
Bullish 0.89
-1.0 0 +1.0
Health Care Sector
Bullish 0.89
-1.0 0 +1.0
Other Patterns Detected Today
Ascending Triangle
40 days in pattern
Good 32.7
Bullish Pennant
22 days in pattern
Moderate 27.0
Overall Score
40 of 40
Exceptional
Pattern Quality
14 of 20
Good
Setup
11 of 20
Fair
R/R
10 of 18
Fair
Context
Pattern Quality Score
15 of 15
Exceptional
Structure
13 of 13
Exceptional
Breakout
12 of 12
Exceptional
Volume
Recent Performance
+0.5%
1W
+4.0%
2W
+5.8%
1M
+2.3%
3M
Momentum & Trend
RSI (14)
54.4
Neutral
MACD Histogram
+0.10
Bullish
Bollinger Band Position
61.5%
Mid Zone
Volatility & Risk
20-Day Volatility
0.31
Moderate
ATR %
2.7%
Medium
Beta
0.67
Below Mkt
Volume Analysis
Volume Ratio
0.60x
Below Avg
20-Day Avg Vol
4.2M
shares / day
Current Volume
2.5M
shares traded
Price Levels
52W High
$60.09
Target
$53.09
Resistance
$51.89
Current
$50.64
Stop Loss
$47.81
Support
$45.82
52W Low
$44.61
Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.